Alethea Capital Management’s Biogen BIIB Stock Holding History

Alethea Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,000	Closed	-$280K	–	90
2021 Q1	$280K	Hold	1,000	–	–	0.17%	65
2020 Q4	$245K	Hold	1,000	–	–	0.12%	66
2020 Q3	$284K	Hold	1,000	–	–	0.19%	55
2020 Q2	$268K	Hold	1,000	–	–	0.16%	72
2020 Q1	$316K	Hold	1,000	–	–	0.2%	57
2019 Q4	$297K	Buy	+1,000	New	+$277K	0.13%	71

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Alethea Capital Management's BIIB Position: Q2 2021 in Review

Alethea Capital Management sold out of Biogen (BIIB) in Q2 2021, closing a stake of 1,000 shares — an estimated $280K sold.

Alethea Capital Management first reported a position in BIIB in Q4 2019 and held it in 6 quarters. The position peaked at $316K in Q1 2020. 1,106 funds tracked by Wall St. Rank hold BIIB as of Q2 2021.

Alethea Capital Management reported no remaining Biogen position as of Q2 2021 after selling out during the quarter.
Alethea Capital Management sold 1,000 Biogen shares in Q2 2021, an estimated $280K.
Alethea Capital Management first reported a position in Biogen in Q4 2019 and held it in 6 quarters.
Alethea Capital Management's Biogen position peaked at $316K in Q1 2020.
1,106 funds tracked by Wall St. Rank held Biogen as of Q2 2021.

Based on Alethea Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.